Advancing neurokinin receptor antagonists in respiratory and women’s health
Innovación y Prurito. Control del prurito: alternativas terapéuticas (Dr. Lluís Ferrer)
'The Antidepressant Drug Pipeline': Jonathan Lipman, PhD
Copywriting Conference 2013: Graeme Archer · 'I am a camera': blogging and human metaphor
Orvepitant (GW823296) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It was under development as a potential antidepressant drug, and early stage human clinical trials showed it to have some antidepressant effects, though not with sufficient efficacy to justify further development for this application. It was however considered a successful proof of concept for NK1 antagonists as potential antidepressants, and efforts are continuing to find more potent compounds which might be more effective.
Explore contextually related video stories in a new eye-catching way. Try Combster now!